(MENAFN- ProactiveInvestors)Chinese and Swiss researchers have published 'Mass spectrometry-based proteomic quest for diabetes biomarkers' in 'Biochimica et Biophysica Acta' an internationally recognized scientific journal suggesting that pressure cycling technology (or PCT) being developed by Pressure BioSciences (OTCQB:PBIO) could be critical in identifying new biomarkers for the early diagnosis progression and underlying pathway dysfunction of diabetes. As such they could also significantly improve the clinical management of this disorder. PBIO is developing PCT based instruments and consumables for a number of areas in scientific research including drug discovery and design cancer and other disease/disorder detection and the analysis of microorganism populations in soil. High pressure is emerging as a powerful tool for understanding protein structure and function delivering direct evidence of the different ways proteins can respond to pressure. In the article the authors which included Dr. Shiying Shao of the Tongji Hospital Huazhong University of Science and Technology (Wuhan PR China) and Drs. Tiannan Guo and Ruedi Aebersold of the Institute of Molecular Systems Biology ETH Zurich (Zurich Switzerland) reviewed the current status of biomarker discovery in diabetes showing the need for limitations and possible solutions for biomarker discovery and validation in the field of diabetes research. Acknowledging the direct role that PCT and PBIO have the study's co-author Professor Aebersold said: 'PCT is a promising sample preparation technology that permits the fast and robust preparation of protein samples from minute amounts of specimen with minimal technical variation.' Diabetes could affect some 366 million people worldwide by 2030. The study noted that even the most recent diabetes research has not been able to overcome significant clinical issues affecting patients including renal retinal and neurological complications. In contrast 'a workflow that combines PCT sample preparation with SWATH-MS next generation proteomics ('PCT-SWATH') may offer vastly improved reproducibility sensitivity and proteome coverage to the diabetes research field' according to co-author Dr. Tiannan Guo. Thus suggest the authors of the study the discovery of new biomarkers for the early diagnosis progression and underlying pathway dysfunction of diabetes is vital to help improve clinical outcome: 'Prediction and early detection of diabetes offer the potential to delay or even reverse the diabetic process. Unfortunately currently available diagnostic markers fail to achieve these goals. Thus it is imperative to identify new biomarkers that offer physicians the ability to evaluate both the necessity and course of medical intervention' said the lead author of the article Dr. Shiying Shao. 'We believe that current diagnostic markers for early diagnosis and progression to complications in diabetes are inadequate and that new next generation methods for the discovery and validation of such biomarkers are needed. We look forward to working with the authors their colleagues and other researchers around the world in the development and expansion of the PCT-SWATH workflow in the important field of diabetes research' said PBI's president and CEO Richard T. Schumacher. PBI develops 'must-have' tools in life sciences research used by many renowned research scientists in proteomics and genomics. The company makes and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Shares of the company were trading at 0.25 cents on Monday.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.